Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences Statistics

Total Valuation

DRUG has a market cap or net worth of $672.50 million. The enterprise value is $612.80 million.

Market Cap	672.50M
Enterprise Value	612.80M

Important Dates

The next estimated earnings date is Friday, February 13, 2026, after market close.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

DRUG has 7.79 million shares outstanding. The number of shares has increased by 59.58% in one year.

Current Share Class	7.79M
Shares Outstanding	7.79M
Shares Change (YoY)	+59.58%
Shares Change (QoQ)	+2.11%
Owned by Insiders (%)	20.40%
Owned by Institutions (%)	39.95%
Float	3.29M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	11.42
P/TBV Ratio	11.42
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 36.10, with a Debt / Equity ratio of 0.00.

Current Ratio	36.10
Quick Ratio	35.68
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-379.73

Financial Efficiency

Return on equity (ROE) is -27.93% and return on invested capital (ROIC) is -19.38%.

Return on Equity (ROE)	-27.93%
Return on Assets (ROA)	-18.80%
Return on Invested Capital (ROIC)	-19.38%
Return on Capital Employed (ROCE)	-16.59%
Revenue Per Employee	n/a
Profits Per Employee	-$337,686
Employee Count	26
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +123.79% in the last 52 weeks. The beta is -0.53, so DRUG's price volatility has been lower than the market average.

Beta (5Y)	-0.53
52-Week Price Change	+123.79%
50-Day Moving Average	71.21
200-Day Moving Average	46.22
Relative Strength Index (RSI)	58.71
Average Volume (20 Days)	288,801

Short Selling Information

The latest short interest is 307,407, so 3.95% of the outstanding shares have been sold short.

Short Interest	307,407
Short Previous Month	270,495
Short % of Shares Out	3.95%
Short % of Float	9.34%
Short Ratio (days to cover)	2.10

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-9.77M
Pretax Income	-8.78M
Net Income	-8.78M
EBITDA	n/a
EBIT	-9.77M
Earnings Per Share (EPS)	-$1.28

Balance Sheet

The company has $59.52 million in cash and $90,299 in debt, with a net cash position of $59.43 million or $7.63 per share.

Cash & Cash Equivalents	59.52M
Total Debt	90,299
Net Cash	59.43M
Net Cash Per Share	$7.63
Equity (Book Value)	58.90M
Book Value Per Share	7.71
Working Capital	58.85M

Cash Flow

Operating Cash Flow	-6.24M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRUG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-59.58%
Shareholder Yield	-59.58%
Earnings Yield	-1.31%
FCF Yield	n/a

Analyst Forecast

The average price target for DRUG is $104.00, which is 15.54% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$104.00
Price Target Difference	15.54%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2023. It was a reverse split with a ratio of 1:5.

Last Split Date	Jul 14, 2023
Split Type	Reverse
Split Ratio	1:5

Scores

Altman Z-Score	n/a
Piotroski F-Score	2